They differ, for instance, in the oncogenic driver mutations, mainly alterations in MAPK signaling in cutaneous melanoma and alterations in GNAQ/GNA11 signaling or the BRCA1-associated protein BAP1 in uveal melanomas (Harbour et al., 2010; Phelps et al., 2022; Van Raamsdonk et al., 2009). This evidence concerns the gene GNA11 and cutaneous melanoma.